[1] JOSEPH L， MICHAEL D， DENNIS F， et al. Retaining and enhancing the QALY [J]. Value Health， 2009， 12(sup 1)：1-4，18-26.
[2] HUFFORD M. Methodological advances in the assessment of quality of life in clinical trials [J]. Value Health， 2008， 4(2)： 181-182.
[3] SCOTT R， RICHARD W， ANDREW B， et al. Good research practices for cost-effectiveness analysis alongside clinical trials： the ISPOR RCT-CEA task force report [J]. Value Health， 2005， 8 (5)： 521-534.
[4] MILTON C W， BERNIE O B， JOHN H， et al. Principles of good practice for decision analytic modeling in health-care evaluation： report of the ISPOR task force on good research practices-modeling studies [J]. Value Health， 2003， 6(1)： 9-17.
[5] KARNON J， GOYDER E， TAPPENDEN P， et al. A review and critique of modelling in prioritising and designing screening programmes[J]. Health Technol Assess， 2007，11(52)：Ⅲ-Ⅳ，Ⅸ-Ⅺ.
[6] PELHAM B， STIRLING B， SUZANNE R. Modelling in the economic evaluation of health care： selecting the appropriate approach [J]. J Health Services Research & Policy， 2004，9(2)： 110-118.
[7] JOHN A V， KEENER W H. A primer on dynamic optimization and optimal control in pharmacoeconomics[J]. Value Health， 2006， 9(2)：106-113.
[8] BENGT L， GO R S K， NILS-OLOV S L. On future non-medical costs in economic evaluations[J]. Health Econ， 2008，17（5）： 579-591.
[9] DAVID R R， PIETER H M B， JOB A E， et al. Unrelated medical costs in life-years gained[J].Pharmacoeconomics， 2008，26(10)：815-830.
[10] LOUIS P G J， PETER J N， PENNIFER E， et al. Using real-world data for coverage and payment decisions： the ISPOR real-world data task force report[J]. Value Health， 2007， 10(5)：326-335.
[11] ANKE-PEGGY H， JOHN B W， DANIEL M， et al. Incorporating observational data into the formulary decision-making process-summary of aroundtable discussion[J]. J Managed Care Pharmacy， 2008， 14(3)： 302-308.
[12] DYFRIG H， WARREN C， TAMAS K， et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations [J]. Value Health， 2007， 10(6)：498-509.
[13] WALLEY T， BRECKENRIDGE A. Pharmacoeconomics comes of age? [J]. Clin Pharmacol Ther， 2008， 84(2)：279-280.
[14] DRUMMOND M， BARBIERI M， COOK J， et al. Transferability of economic evaluations across jurisdictions： ISPOR good research practices task force report[J]. Value Health， 2009， 12(4)：1-32.
[15] JAMES M M， ANNE R M. The generalisability of pharmacoeconomic studies issues and challenges ahead[J]. Pharmacoeconomics， 2006， 24 (10)： 937-945.
[16] SCULPHER M J， PANG F S， MANCA A， et al. Generalisability in economic evaluation studies in healthcare： a review and case studies [J].Health Technol Assess， 2004， 8(49)：Ⅲ-Ⅳ.
[17] JOSEPHINE A M， SEAN D S， LIEVEN A， et al. Principles of good practice for budget impact analysis： report of the ISPOR task force on good research practices-budget impact analysis [J]. Value Health， 2007， 10(5)：336-347.
[18] MARSHALL， DEBORAH A， DOUGLAS ， et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada [J]. Pharmacoeconomics， 2008， 26(6)： 477-495.
[19] ORLEWSKA E， GULACSI L. Budget-impact analyses： a critical review of published studies [J]. Pharmacoeconomics， 2009， 27(10)： 807-827.
[20] WILLIAM F M， MAIWENN A， JALPA A D. The ISPOR good practices for quality improvement of cost-effectiveness research task force report[J]. Value Health， 2009，12（8）：1086-1099.